AM25-ST-25-L - AABB/THOR Joint Session: Some New Looks at Old Dogma, New Studies, and New Blood Products

Saturday, October 25, 2025

8:15 AM - 12:15 PM PT

Location: 20A

Program Chair(s)

Audra L. Taylor, MS, SBB(ASCP)

Vice President, Blood and Tissue Operations
South Texas Blood & Tissue
San Antonio, Texas

Disclosure information not submitted.
Bethany Brown

Sr. Director, Transfusion Innovation & Product Development
American Red Cross
Rockville, Maryland

Disclosure information not submitted.

Speaker(s)

Evan M. Bloch, MBChB, MS

Professor of Pathology
Johns Hopkins University School of Medicine
Baltimore, Maryland

Disclosure(s): No relevant disclosure to display
Claudia Cohn, MD, PhD (she/her/hers)

Professor of Laboratory Medicine and Pathology, Director, Blood Bank Laboratory
University of Minnesota
Minneapolis, Minnesota

Disclosure(s): No relevant disclosure to display
Martin H. Ellis, n/a (he/him/his)

Director, Blood Bank
Meir Medical Center
Kfar Saba, HaMerkaz

Disclosure(s): No financial relationships to disclose
John Holcomb, MD, FACS

Professor of Surgery
The Geneva Foundation
Birmingham, Alabama

Disclosure(s): No relevant disclosure to display
RM

Ryan A. Metcalf, MD

Section Chief, Transfusion Medicine
University of Utah Health
Salt Lake City, Utah

Disclosure(s): No relevant disclosure to display
Jay S. Raval, MD

Professor, Department. of Pathology and Laboratory Medicine
University of Vermont Medical Center
Burlington, Vermont

Disclosure(s): No relevant disclosure to display
Susan M. Shea, MSME, PhD (she/her/hers)

Assistant Professor
Trauma and Transfusion Medicine Research Center, Department of Surgery, University of Pittsburgh
Pittsburgh, Pennsylvania

Disclosure(s): No financial relationships to disclose
Molly Sherwood

Director of Research
Allo Hope Foundation, Alabama

Disclosure(s): No financial relationships to disclose
Nicole D. Zantek, MD, PhD

Professor
Department of Laboratory Medicine and Pathology, University of Minnesota
Minneapolis, Minnesota

Disclosure(s): No relevant disclosure to display

This joint session organized by the Trauma, Hemostasis and Oxygenation Research (THOR) Network and the Association for the Advancement of Blood and Biotherapies (AABB), will look both backwards and forwards in time to update the audience on the best practices in providing blood products to patients with life threatening hemorrhage. Some long-held beliefs about hemolysis, platelet production methods, and transfusion futility will be challenged, and an update from the Emergency transfusion in females with childbearing potential consensus conference will be provided, along discussions of cold platelets, liquid plasma, and more.

8:15 – 9:15 Blood Management aspects of Hemostatic Resuscitation
• Liquid plasma as a substitute for whole blood –John Holcomb
• Improving LTOWB availability by reducing inappropriate Group O RBC use – Ryan Metcalf
• Plasma exchange for trauma induced coagulopathy - Jay Raval
• Panel Discussion
09:15 – 9:30 Break
9:30 – 10:30 Changing Practice with LTOWB
• Review of the recommendations from the Emergency transfusion in females with childbearing potential consensus conference – Molly Sherwood
• It’s on! The use of low titer group O whole blood in non-trauma patients – Martin Ellis
• Why are some hospitals not implementing LTOWB? – Evan Bloch
• Panel Discussion
10:30 – 10:45 Break
10:45 – 12:15 Blood Management aspects of Hemostatic Resuscitation (1045-1215)
• CHIPS study update – Nicole Zantek
• Platelet manufacturing methods and platelet quality – Susan Shea
• FDA Guidance and what it means for you – Claudia Cohn
• Panel Discussion

Learning Objectives:

Analyze the outcomes of the CHiPS study.
Update on the recommendations of a consensus conference on the optimum strategies for resuscitating injured females of childbearing. potential.
Learn about the role of plasma exchange in treating trauma induced coagulopathy.